Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | saliva | DOI[10.1007/s11306-015-0840-5] | ||
NPO20338 | Mus musculus | Species | Muridae | Eukaryota |
PMID[19425150] |
|||
NPO730 | Escherichia coli | Species | Enterobacteriaceae | Bacteria |
PMID[21988831] |
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT3825 | Individual Protein | Purinergic receptor P2Y1 | Homo sapiens | EC50 | > | 100000 | nM | 12213051 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 140 | nM | 12213051 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 2500 | nM | 12213051 |
NPT3828 | Individual Protein | Pyrimidinergic receptor P2Y4 | Rattus norvegicus | EC50 | = | 2600 | nM | 12213051 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 6000 | nM | 12213051 |
NPT3829 | Individual Protein | Purinergic receptor P2Y11 | Homo sapiens | EC50 | > | 100000 | nM | 12213051 |
NPT3830 | Individual Protein | N-acetyllactosaminide alpha-1,3-galactosyltransferase | Mus musculus | Ki | = | 128000 | nM | 3475471 |
NPT2881 | Individual Protein | Beta-1,4-galactosyltransferase 1 | Bos taurus | Ki | = | 128000 | nM | 10.1016/S0960-894X(00)80055-4 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 30 | nM | 11206448 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 100 | nM | 11206448 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | > | 10000 | nM | 11206448 |
NPT2672 | Individual Protein | Dihydroorotase | Homo sapiens | Activity | = | 18 | % | 10.1016/0960-894X(96)00452-0 |
NPT3832 | Individual Protein | Purinergic receptor P2Y2 | Rattus norvegicus | EC50 | = | 130 | nM | 16539385 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 450 | nM | 16539385 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 43 | nM | 17125260 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 87 | nM | 17125260 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | > | 10000 | nM | 17302398 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 49 | nM | 17302398 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 73 | nM | 17302398 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 109.65 | nM | 17941622 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 7 | nM | 17011188 |
NPT3825 | Individual Protein | Purinergic receptor P2Y1 | Homo sapiens | EC50 | > | 2000 | nM | 17011188 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 39 | nM | 17011188 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 424 | nM | 17011188 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 7 | nM | 17079144 |
NPT3825 | Individual Protein | Purinergic receptor P2Y1 | Homo sapiens | EC50 | > | 2000 | nM | 17079144 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 39 | nM | 17079144 |
NPT2 | Others | Unspecified | EC50 | = | 424 | nM | 17079144 | |
NPT2 | Others | Unspecified | Ki | = | 100000 | nM | 17329110 | |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 640 | nM | 18760862 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 480 | nM | 18760862 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 60 | nM | 18514530 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 90 | nM | 18514530 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | > | 10000 | nM | 18514530 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 80.4 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 2090 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | Ratio EC50 | = | 25 | 19419204 | |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 37.2 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 59 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 124 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 50.1 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 138 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 20600 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 157 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 121 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 108 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | > | 300000 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | Ratio EC50 | = | 2 | 19419204 | |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 781 | nM | 19419204 |
NPT3833 | Individual Protein | Purinergic receptor P2Y2 | Mus musculus | IC50 | = | 1510 | nM | 19523835 |
NPT3833 | Individual Protein | Purinergic receptor P2Y2 | Mus musculus | EC50 | = | 1260 | nM | 19523835 |
NPT3833 | Individual Protein | Purinergic receptor P2Y2 | Mus musculus | Activity | = | 40 | % | 19523835 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 100 | nM | 20095577 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 500 | nM | 20095577 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 90 | nM | 20446735 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 60 | nM | 20446735 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | Activity | <= | 50 | % | 20446735 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | > | 10000 | nM | 20446735 |
NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | = | 39810.7 | nM | PubChem BioAssay data set |
NPT583 | Individual Protein | Inositol monophosphatase 1 | Rattus norvegicus | Potency | = | 28183.8 | nM | PubChem BioAssay data set |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 17.9 | nM | 21417463 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 88.4 | nM | 21417463 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | = | 6000 | nM | 21417463 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 60 | nM | 21528910 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 90 | nM | 21528910 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 55 | nM | 21528910 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 80 | nM | 21528910 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | > | 10000 | nM | 21528910 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | Ratio EC50 | = | 5 | 21528910 | |
NPT698 | Individual Protein | Regulator of G-protein signaling 4 | Homo sapiens | Potency | 1683.4 | nM | PubChem BioAssay data set | |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 640 | nM | 22107038 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 480 | nM | 22107038 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 20 | nM | 22386981 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 140 | nM | 22901672 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 900 | nM | 22901672 |
NPT49 | Individual Protein | DNA-(apurinic or apyrimidinic site) lyase | Homo sapiens | Potency | 2818.4 | nM | PubChem BioAssay data set |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC73765 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
1.0 | High Similarity | NPC283698 |
0.9885 | High Similarity | NPC36985 |
0.9885 | High Similarity | NPC17892 |
0.9655 | High Similarity | NPC320249 |
0.9655 | High Similarity | NPC322594 |
0.954 | High Similarity | NPC324390 |
0.9121 | High Similarity | NPC317639 |
0.908 | High Similarity | NPC43246 |
0.908 | High Similarity | NPC89051 |
0.8969 | High Similarity | NPC329277 |
0.8788 | High Similarity | NPC149843 |
0.8788 | High Similarity | NPC155087 |
0.8736 | High Similarity | NPC106780 |
0.8602 | High Similarity | NPC324516 |
0.8602 | High Similarity | NPC318166 |
0.8587 | High Similarity | NPC327344 |
0.837 | Intermediate Similarity | NPC315063 |
0.8229 | Intermediate Similarity | NPC120887 |
0.8152 | Intermediate Similarity | NPC163352 |
0.8152 | Intermediate Similarity | NPC210456 |
0.8144 | Intermediate Similarity | NPC328779 |
0.8125 | Intermediate Similarity | NPC226769 |
0.8125 | Intermediate Similarity | NPC280946 |
0.8125 | Intermediate Similarity | NPC6166 |
0.798 | Intermediate Similarity | NPC328914 |
0.7857 | Intermediate Similarity | NPC90240 |
0.7835 | Intermediate Similarity | NPC329384 |
0.7826 | Intermediate Similarity | NPC71339 |
0.7826 | Intermediate Similarity | NPC112842 |
0.7742 | Intermediate Similarity | NPC325723 |
0.764 | Intermediate Similarity | NPC329077 |
0.7632 | Intermediate Similarity | NPC284651 |
0.7423 | Intermediate Similarity | NPC171116 |
0.7396 | Intermediate Similarity | NPC190334 |
0.7396 | Intermediate Similarity | NPC62927 |
0.7083 | Intermediate Similarity | NPC229249 |
0.6989 | Remote Similarity | NPC325902 |
0.6634 | Remote Similarity | NPC328806 |
0.6557 | Remote Similarity | NPC315058 |
0.6531 | Remote Similarity | NPC319753 |
0.64 | Remote Similarity | NPC313962 |
0.6383 | Remote Similarity | NPC315806 |
0.625 | Remote Similarity | NPC109188 |
0.6239 | Remote Similarity | NPC478024 |
0.6129 | Remote Similarity | NPC325750 |
0.6077 | Remote Similarity | NPC318142 |
0.5691 | Remote Similarity | NPC313813 |
0.56 | Remote Similarity | NPC470782 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC73765 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
1.0 | High Similarity | NPD9639 | Clinical (unspecified phase) |
0.908 | High Similarity | NPD9581 | Clinical (unspecified phase) |
0.908 | High Similarity | NPD9580 | Clinical (unspecified phase) |
0.8969 | High Similarity | NPD3129 | Phase 3 |
0.8866 | High Similarity | NPD3128 | Phase 3 |
0.8539 | High Similarity | NPD9557 | Clinical (unspecified phase) |
0.8208 | Intermediate Similarity | NPD3139 | Phase 3 |
0.8113 | Intermediate Similarity | NPD3138 | Phase 3 |
0.8105 | Intermediate Similarity | NPD1686 | Approved |
0.809 | Intermediate Similarity | NPD9556 | Approved |
0.8085 | Intermediate Similarity | NPD9565 | Discontinued |
0.8061 | Intermediate Similarity | NPD5789 | Clinical (unspecified phase) |
0.8 | Intermediate Similarity | NPD9561 | Approved |
0.8 | Intermediate Similarity | NPD9560 | Approved |
0.798 | Intermediate Similarity | NPD1455 | Phase 3 |
0.798 | Intermediate Similarity | NPD1454 | Phase 3 |
0.7979 | Intermediate Similarity | NPD755 | Phase 3 |
0.7912 | Intermediate Similarity | NPD9546 | Phase 2 |
0.7889 | Intermediate Similarity | NPD9558 | Phase 3 |
0.7826 | Intermediate Similarity | NPD280 | Approved |
0.7826 | Intermediate Similarity | NPD9533 | Phase 2 |
0.7778 | Intermediate Similarity | NPD502 | Approved |
0.7766 | Intermediate Similarity | NPD241 | Discontinued |
0.766 | Intermediate Similarity | NPD9562 | Discovery |
0.766 | Intermediate Similarity | NPD240 | Phase 3 |
0.766 | Intermediate Similarity | NPD170 | Approved |
0.7593 | Intermediate Similarity | NPD7914 | Suspended |
0.7527 | Intermediate Similarity | NPD9559 | Phase 1 |
0.7527 | Intermediate Similarity | NPD9529 | Phase 1 |
0.7475 | Intermediate Similarity | NPD501 | Phase 1 |
0.7447 | Intermediate Similarity | NPD238 | Clinical (unspecified phase) |
0.7447 | Intermediate Similarity | NPD239 | Phase 2 |
0.7429 | Intermediate Similarity | NPD6946 | Approved |
0.7423 | Intermediate Similarity | NPD841 | Approved |
0.7396 | Intermediate Similarity | NPD9604 | Approved |
0.7396 | Intermediate Similarity | NPD9603 | Phase 3 |
0.7396 | Intermediate Similarity | NPD9602 | Phase 3 |
0.7327 | Intermediate Similarity | NPD762 | Discontinued |
0.7273 | Intermediate Similarity | NPD251 | Approved |
0.7238 | Intermediate Similarity | NPD1061 | Clinical (unspecified phase) |
0.71 | Intermediate Similarity | NPD6943 | Clinical (unspecified phase) |
0.71 | Intermediate Similarity | NPD9585 | Discontinued |
0.7083 | Intermediate Similarity | NPD9601 | Approved |
0.7041 | Intermediate Similarity | NPD1760 | Approved |
0.6957 | Remote Similarity | NPD7756 | Clinical (unspecified phase) |
0.6952 | Remote Similarity | NPD223 | Clinical (unspecified phase) |
0.6881 | Remote Similarity | NPD1385 | Discontinued |
0.6827 | Remote Similarity | NPD514 | Clinical (unspecified phase) |
0.6822 | Remote Similarity | NPD7651 | Approved |
0.68 | Remote Similarity | NPD301 | Discontinued |
0.68 | Remote Similarity | NPD9553 | Approved |
0.68 | Remote Similarity | NPD9554 | Approved |
0.6797 | Remote Similarity | NPD7761 | Suspended |
0.6771 | Remote Similarity | NPD9600 | Approved |
0.6699 | Remote Similarity | NPD279 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD267 | Discontinued |
0.6633 | Remote Similarity | NPD9572 | Clinical (unspecified phase) |
0.6581 | Remote Similarity | NPD7992 | Clinical (unspecified phase) |
0.6542 | Remote Similarity | NPD192 | Phase 2 |
0.6531 | Remote Similarity | NPD9573 | Phase 2 |
0.6505 | Remote Similarity | NPD500 | Discontinued |
0.6476 | Remote Similarity | NPD215 | Discontinued |
0.6383 | Remote Similarity | NPD9653 | Clinical (unspecified phase) |
0.6337 | Remote Similarity | NPD9555 | Phase 2 |
0.6327 | Remote Similarity | NPD9429 | Discontinued |
0.6292 | Remote Similarity | NPD9503 | Approved |
0.6292 | Remote Similarity | NPD9504 | Approved |
0.6262 | Remote Similarity | NPD6948 | Phase 3 |
0.625 | Remote Similarity | NPD9407 | Approved |
0.625 | Remote Similarity | NPD2633 | Phase 1 |
0.625 | Remote Similarity | NPD4743 | Phase 2 |
0.625 | Remote Similarity | NPD1331 | Approved |
0.6224 | Remote Similarity | NPD9427 | Approved |
0.6207 | Remote Similarity | NPD1805 | Phase 2 |
0.6207 | Remote Similarity | NPD1804 | Phase 2 |
0.614 | Remote Similarity | NPD1428 | Phase 2 |
0.6121 | Remote Similarity | NPD284 | Phase 1 |
0.604 | Remote Similarity | NPD2691 | Clinical (unspecified phase) |
0.6034 | Remote Similarity | NPD6693 | Phase 3 |
0.5946 | Remote Similarity | NPD3121 | Phase 2 |
0.5938 | Remote Similarity | NPD9405 | Approved |
0.5922 | Remote Similarity | NPD205 | Approved |
0.5902 | Remote Similarity | NPD6935 | Phase 3 |
0.5902 | Remote Similarity | NPD6936 | Clinical (unspecified phase) |
0.59 | Remote Similarity | NPD9403 | Discontinued |
0.5893 | Remote Similarity | NPD765 | Discontinued |
0.5833 | Remote Similarity | NPD285 | Discontinued |
0.5739 | Remote Similarity | NPD244 | Clinical (unspecified phase) |
0.5727 | Remote Similarity | NPD1706 | Clinical (unspecified phase) |
PubChem CID   | 6133 |
ChEMBL   | CHEMBL336296 |
ZINC   |
Molecular Weight:   | 483.97 |
ALogP:   | -3.0419 |
MLogP:   | 0.25 |
XLogP:   | -5.898 |
# Rotatable Bonds:   | 15 |
Polar Surface Area:   | 291.84 |
# H-Bond Aceptor:   | 17 |
# H-Bond Donor:   | 7 |
# Rings:   | 2 |
# Heavy Atoms:   | 29 |